Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials.
Cholesterol
Lipid profile
Meta-analysis
Synbiotics
Triglyceride
Journal
European journal of nutrition
ISSN: 1436-6215
Titre abrégé: Eur J Nutr
Pays: Germany
ID NLM: 100888704
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
11
2019
accepted:
01
04
2020
pubmed:
24
4
2020
medline:
24
6
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
Existing evidence on the possible effects of synbiotics on lipid profile is inconclusive. The aim of the present systematic review was to clarify the effects of synbiotics consumption on lipid profile. A systematic literature search of online databases PubMed, Scopus, ISI Web of science, Cochrane's library and Google Scholar was conducted up to January 2019. Randomized controlled trials (RCTs) investigating the effects of synbiotics on lipid profile in adults were included. The overall effect was presented as weighted mean difference (WMD) and 95% confidence interval (CI) in a random-effects meta-analysis model. A total of 23 RCTs with 1338 participants were included. Synbiotic consumption resulted in a significant decrease in plasma concentrations of total cholesterol (WMD = - 10.17 mg/dL; 95% CI - 15.74 to - 4.60; p < 0.001), triglyceride (WMD = - 14.30 mg/dL; 95% CI - 25.32 to - 3.28; p = 0.01), low-density lipoprotein cholesterol (WMD = - 8.32 mg/dL; 95% CI - 13.21 to - 3.43; p < 0.001), and an increase in plasma high-density lipoprotein cholesterol (WMD = 1.3 mg/dL; 95% CI 0.03 to 2.56; p = 0.04) levels compared to control (placebo supplements/control foods/conventional products). The effects are more pronounced when synbiotics supplements are consumed for > 8 weeks. Synbiotic supplements may be beneficial to improve lipid profile, especially when they are consumed for > 8 weeks.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Existing evidence on the possible effects of synbiotics on lipid profile is inconclusive. The aim of the present systematic review was to clarify the effects of synbiotics consumption on lipid profile.
METHODS
METHODS
A systematic literature search of online databases PubMed, Scopus, ISI Web of science, Cochrane's library and Google Scholar was conducted up to January 2019. Randomized controlled trials (RCTs) investigating the effects of synbiotics on lipid profile in adults were included. The overall effect was presented as weighted mean difference (WMD) and 95% confidence interval (CI) in a random-effects meta-analysis model.
RESULTS
RESULTS
A total of 23 RCTs with 1338 participants were included. Synbiotic consumption resulted in a significant decrease in plasma concentrations of total cholesterol (WMD = - 10.17 mg/dL; 95% CI - 15.74 to - 4.60; p < 0.001), triglyceride (WMD = - 14.30 mg/dL; 95% CI - 25.32 to - 3.28; p = 0.01), low-density lipoprotein cholesterol (WMD = - 8.32 mg/dL; 95% CI - 13.21 to - 3.43; p < 0.001), and an increase in plasma high-density lipoprotein cholesterol (WMD = 1.3 mg/dL; 95% CI 0.03 to 2.56; p = 0.04) levels compared to control (placebo supplements/control foods/conventional products). The effects are more pronounced when synbiotics supplements are consumed for > 8 weeks.
CONCLUSION
CONCLUSIONS
Synbiotic supplements may be beneficial to improve lipid profile, especially when they are consumed for > 8 weeks.
Identifiants
pubmed: 32322969
doi: 10.1007/s00394-020-02248-7
pii: 10.1007/s00394-020-02248-7
doi:
Substances chimiques
Cholesterol, LDL
0
Lipids
0
Triglycerides
0
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2857-2874Références
Bedani R, Rossi EA, Cavallini DCU, Pinto RA, Vendramini RC, Augusto EM, Abdalla DSP, Saad SMI (2015) Influence of daily consumption of synbiotic soy-based product supplemented with okara soybean by-product on risk factors for cardiovascular diseases. Food Res Int 73:142–148
doi: 10.1016/j.foodres.2014.11.006
Goff DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM (2006) Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA). Circulation 113(5):647–656. https://doi.org/10.1161/CIRCULATIONAHA.105.552737
doi: 10.1161/CIRCULATIONAHA.105.552737
pubmed: 16461837
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115(1):114–126
pubmed: 17192512
doi: 10.1161/CIRCULATIONAHA.106.179294
National Institutes of Health (2001) Third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), vol 285. National Institutes of Health, Bethesda, MD, pp 2486–2497
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA (2019) Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk”. Atherosclerosis 290(2019):140–205
doi: 10.1016/j.atherosclerosis.2019.08.014
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ (2015) Dysbiosis of the gut microbiota in disease. Microbial Ecol Health Dis 26(1):26191
Chang C, Lin H (2016) Dysbiosis in gastrointestinal disorders. Best Pract Res Clin Gastroenterol 30(1):3–15
pubmed: 27048892
doi: 10.1016/j.bpg.2016.02.001
Gérard P (2016) Gut microbiota and obesity. Cell Mol Life Sci 73(1):147–162
pubmed: 26459447
doi: 10.1007/s00018-015-2061-5
Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363(14):1341–1350
pubmed: 20879883
doi: 10.1056/NEJMra0912063
Sayari S, Neishaboori H, Jameshorani M (2018) Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin Mol Hepatol 24(3):331
pubmed: 29890569
pmcid: 6166102
doi: 10.3350/cmh.2018.0006
Hotel ACP, Cordoba A (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention 5(1):1–10
Gibson GR, Probert HM, Van Loo J, Rastall RA, Roberfroid MB (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17(2):259–275
pubmed: 19079930
doi: 10.1079/NRR200479
De Vrese M, Schrezenmeir AJ (2008) Probiotics, prebiotics, and synbiotics. In: Food biotechnology. Springer, Berlin, Heidelberg, pp 1–66
Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341
pubmed: 20171303
doi: 10.1016/j.ijsu.2010.02.007
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
pubmed: 3196245
pmcid: 3196245
doi: 10.1136/bmj.d5928
Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45(7):769–773
pubmed: 1619456
doi: 10.1016/0895-4356(92)90054-Q
Green S. Higgins J (2005) Cochrane handbook for systematic reviews of interventions. Version
Asemi Z, Khorrami-Rad A, Alizadeh S-A, Shakeri H, Esmaillzadeh A (2014) Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33(2):198–203
pubmed: 23786900
doi: 10.1016/j.clnu.2013.05.015
Asgharian A, Mohammadi V, Gholi Z, Esmaillzade A, Feizi A, Askari G (2017) The effect of synbiotic supplementation on body composition and lipid profile in patients with NAFLD: a randomized, double blind, placebo-controlled clinical trial study. Iranian Red Crescent Med J 19(4):e42902
doi: 10.5812/ircmj.42902
Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M (2018) Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr 148(8):1276–1284
pubmed: 29931231
doi: 10.1093/jn/nxy088
Ekhlasi G, Kolahdouz Mohammadi R, Agah S, Zarrati M, Hosseini AF, Arabshahi SS, Shidfar F (2016) Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci 21:106. https://doi.org/10.4103/1735-1995.193178
doi: 10.4103/1735-1995.193178
pubmed: 28250783
pmcid: 5322689
Eslamparast T, Zamani F, Hekmatdoost A, Sharafkhah M, Eghtesad S, Malekzadeh R, Poustchi H (2014) Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br J Nutr 112(3):438–445
pubmed: 24848793
doi: 10.1017/S0007114514000919
Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari MdLA, Vilela EG, Torres HO, Cunha AS (2016) Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients 8(7):397
pmcid: 4963873
doi: 10.3390/nu8070397
Javadi L, Ghavami M, Khoshbaten M, Safaiyan A, Barzegari A, Gargari BP (2017) The potential role of probiotics or/and prebiotic on serum lipid profile and insulin resistance in alcoholic fatty liver disease: a double blind randomized clinical trial. Crescent J Med Biol Sci 4:131–138
Macfarlane S, Cleary S, Bahrami B, Reynolds N, Macfarlane G (2013) Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. Aliment Pharmacol Ther 38(7):804–816
pubmed: 23957631
doi: 10.1111/apt.12453
Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Volti GL (2012) Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57(2):545–553
pubmed: 21901256
doi: 10.1007/s10620-011-1887-4
Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A (2017) Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr 117(5):662–668
pubmed: 28345499
doi: 10.1017/S0007114517000204
Moroti C, Magri LFS, de Rezende CM, Cavallini DC, Sivieri K (2012) Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 11(1):29
pubmed: 22356933
pmcid: 3305430
doi: 10.1186/1476-511X-11-29
Peña F, Mizgier ML, Morales P, Rios I, Carrasco-Pozo C, Diaz E, Brunser O, Gotteland M (2014) Effect of the synbiotic (B. animalis spp. lactis Bb12+ oligofructose) in obese subjects. A randomized, double-blind, controlled clinical trial. J Food Nutr Res 2:491–498
doi: 10.12691/jfnr-2-8-10
Rabiei S, Hedayati M, Rashidkhani B, Saadat N, Shakerhossini R (2019) The effects of synbiotic supplementation on body mass index, metabolic and inflammatory biomarkers, and appetite in patients with metabolic syndrome: a Triple-Blind randomized controlled trial. J Dietary Suppl 16(3):294–306
doi: 10.1080/19390211.2018.1455788
Sadat Ebrahimi Z, Nasli-Esfahani E, Nadjarzade A, Mozaffari-khosravi H (2017) Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial. J Diabetes Metab Disord 16(1):23
doi: 10.1186/s40200-017-0304-8
Samimi M, Dadkhah A, Kashani HH, Tajabadi-Ebrahimi M, Hosseini ES, Asemi Z (2019) The effects of synbiotic supplementation on metabolic status in women with polycystic ovary syndrome: a randomized double-blind clinical trial. Probiotics Antimicrob Proteins 11(4):1355–61
pubmed: 29532416
doi: 10.1007/s12602-018-9405-z
Sanchez M, Darimont C, Drapeau V, Emady-Azar S, Lepage M, Rezzonico E, Ngom-Bru C, Berger B, Philippe L, Ammon-Zuffrey C (2014) Effect of Lactobacillus rhamnosus CGMCC1. 3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr 111(8):1507–1519
pubmed: 24299712
doi: 10.1017/S0007114513003875
Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N, Ghandi Y, Asemi Z (2014) Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids 49(7):695–701
pubmed: 24706266
doi: 10.1007/s11745-014-3901-z
Soleimani A, Motamedzadeh A, Mojarrad MZ, Bahmani F, Amirani E, Ostadmohammadi V, Tajabadi-Ebrahimi M, Asemi Z (2019) The effects of synbiotic supplementation on metabolic status in diabetic patients undergoing hemodialysis: a randomized, double-Blinded, placebo-controlled trial. Probiot Antimicrob Proteins 11(4):1248–56
doi: 10.1007/s12602-018-9499-3
Tajabadi-Ebrahimi M, Sharifi N, Farrokhian A, Raygan F, Karamali F, Razzaghi R, Taheri S, Asemi Z (2017) A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease. Exp Clin Endocrinol Diabetes 125(01):21–27
pubmed: 27219886
Xavier-Santos D, Lima ED, Simão ANC, Bedani R, Saad SMI (2018) Effect of the consumption of a synbiotic diet mousse containing Lactobacillus acidophilus La-5 by individuals with metabolic syndrome: a randomized controlled trial. J Funct Foods 41:55–61
doi: 10.1016/j.jff.2017.12.041
Zamani B, Farshbaf S, Golkar HR, Bahmani F, Asemi Z (2017) Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial. Br J Nutr 117(8):1095–1102
pubmed: 28490394
doi: 10.1017/S000711451700085X
Mohammadi H, Miraghajani M, Ghaedi E (2018) Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD AU - Hadi. Crit Rev Food Sci Nutr. https://doi.org/10.1080/10408398.2018.1458021
doi: 10.1080/10408398.2018.1458021
pubmed: 30595036
Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, Molle D, Lortal S, Altermann E, Klaenhammer TR, Van Kooyk Y (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci 105(49):19474–19479
pubmed: 19047644
doi: 10.1073/pnas.0810305105
Ouwehand AC, Tiihonen K, Saarinen M, Putaala H, Rautonen N (2008) Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters. Br J Nutr 101(3):367–375
pubmed: 18634707
doi: 10.1017/S0007114508003097
Brubaker SW, Bonham KS, Zanoni I, Kagan JC (2015) Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 33:257–290. https://doi.org/10.1146/annurev-immunol-032414-112240
doi: 10.1146/annurev-immunol-032414-112240
pubmed: 25581309
pmcid: 5146691
Dasu MR, Devaraj S, Park S, Jialal I (2010) Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33(4):861–868
pubmed: 20067962
pmcid: 2845042
doi: 10.2337/dc09-1799
Kimoto H, Ohmomo S, Okamoto T (2002) Cholesterol removal from media by Lactococci. J Dairy Sci 85(12):3182–3188
pubmed: 12512591
doi: 10.3168/jds.S0022-0302(02)74406-8
Lye H-S, Rusul G, Liong M-T (2010) Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. J Dairy Sci 93(4):1383–1392
pubmed: 20338415
doi: 10.3168/jds.2009-2574
Begley M, Hill C, Gahan CG (2006) Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 72(3):1729–1738
pubmed: 16517616
pmcid: 1393245
doi: 10.1128/AEM.72.3.1729-1738.2006
Patel AK, Singhania RR, Pandey A, Chincholkar SB (2010) Probiotic bile salt hydrolase: current developments and perspectives. Appl Biochem Biotechnol 162(1):166–180
pubmed: 19669939
doi: 10.1007/s12010-009-8738-1
De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, Verbeke K (2007) Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointestinal Liver Physiol 292(1):G358–G368
doi: 10.1152/ajpgi.00052.2006
Zhuang G, Liu X-M, Zhang Q-X, Tian F-W, Zhang H, Zhang H-P, Chen W (2012) Research advances with regards to clinical outcome and potential mechanisms of the cholesterol-lowering effects of probiotics. Clin Lipidol 7(5):501–507
doi: 10.2217/clp.12.40
Leung C, Rivera L, Furness JB, Angus PW (2016) The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13(7):412
pubmed: 27273168
doi: 10.1038/nrgastro.2016.85
Lee J, Hong S-W, Rhee E-J, Lee W-Y (2012) GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J 36(4):262–267
pubmed: 22950055
pmcid: 3428412
doi: 10.4093/dmj.2012.36.4.262
Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837
pubmed: 23684623
doi: 10.1016/j.cmet.2013.04.008
Wojdemann M, Wettergren A, Sternby B, Holst JJ, Larsen S, Rehfeld JF, Olsen O (1998) Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Dig Dis Sci 43(4):799–805
pubmed: 9558037
doi: 10.1023/A:1018874300026
Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A (2017) Effects of curcumin on HDL functionality. Pharmacol Res 119:208–218
pubmed: 28192240
doi: 10.1016/j.phrs.2017.02.008
Ali KM, Wonnerth A, Huber K, Wojta J (2012) Cardiovascular disease risk reduction by raising HDL cholesterol–current therapies and future opportunities. Br J Pharmacol 167(6):1177–1194
pmcid: 3504986
doi: 10.1111/j.1476-5381.2012.02081.x